TrialPigment cell & melanoma research2018

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.

Alain P Algazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.